Literature DB >> 32188803

Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer.

Takaaki Kishino1,2, Tsuneo Oyama1, Akihisa Tomori3, Akiko Takahashi1, Tomoaki Shinohara3.   

Abstract

Objective The aim of the present study was to evaluate the effectiveness and limitations of a serum screening system for predicting the risk of gastric cancer. Methods Serum pepsinogen I (PG I)/pepsinogen II (PG II) and Helicobacter pylori (HP) antibody levels were measured. Subjects were classified into four groupsaccording to their serological status (the ABC classification system). The grade of atrophic gastritis was assessed endoscopically. We evaluated gastric cancer detection rates according to the ABC classification system and the endoscopic grade of atrophy. Patients Individuals who underwent esophagogastroduodenoscopy (EGD) in a health check were prospectively enrolled in the present study. Results According to the ABC classification system, the gastric cancer detection rates in groups A, B, C, and D were 0.07% (4/6,105), 0.5% (8/1,739), 0.8% (16/2,010), and 1.1% (3/281), respectively. The gastric cancer detection rates in subjects with no atrophy, closed type (C-type) atrophy, and open type (O-type) atrophy were 0% (0/4,567), 0.2% (4/2,581), and 0.9% (27/2,987), respectively. In group A (HP(-)/PG(-)), the proportions of subjects with no atrophy, C-type atrophy, and O-type atrophy were 71.2%, 22.8%, and 6.0%, respectively. In group A, the gastric cancer detection rates in subjects with no atrophy, C-type atrophy, and O-type atrophy were 0%, 0.07%, and 0.8%, respectively. Conclusion The ABC classification system is useful for predicting the risk of gastric cancer. However, this system was limited in group A, which included individuals with a high risk of developing gastric cancer. An endoscopic diagnosis of atrophy may be more effective than the ABC classification system for predicting the risk of gastric cancer.

Entities:  

Keywords:  Helicobacter pylori; atrophic; gastritis; pepsinogens; serological risk prediction system; stomach neoplasms

Year:  2020        PMID: 32188803     DOI: 10.2169/internalmedicine.3521-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  Application of a novel scoring system for gastric cancer opportunistic screening in hospital visits.

Authors:  Qingjie Zhou; Yihan Chen; Jie Pan; Leying Zhou; Jiejun Lin
Journal:  BMC Gastroenterol       Date:  2022-05-08       Impact factor: 2.847

Review 2.  Gastric Cancer Screening in Japan: A Narrative Review.

Authors:  Kazuo Yashima; Michiko Shabana; Hiroki Kurumi; Koichiro Kawaguchi; Hajime Isomoto
Journal:  J Clin Med       Date:  2022-07-26       Impact factor: 4.964

3.  Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study.

Authors:  Nicolas Chapelle; Malgorzata Osmola; Jérôme Martin; Justine Blin; Maxime Leroy; Iva Jirka; Driffa Moussata; Dominique Lamarque; Raphael Olivier; David Tougeron; Anne Hay-Lombardie; Edith Bigot-Corbel; Damien Masson; Jean-François Mosnier; Tamara Matysiak-Budnik
Journal:  Diagnostics (Basel)       Date:  2022-03-12

4.  Incidence of Infection among Subjects with Helicobacter pylori Seroconversion.

Authors:  Young Jung Kim; Sun-Young Lee; Jeong Hwan Kim; In-Kyung Sung; Hyung Seok Park
Journal:  Clin Endosc       Date:  2021-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.